Exact Sciences Corp. (Nasdaq: EXAS) today announced that it has obtained a worldwide license from Hologic Inc. for that company’s Invader, Invader plus and real-time Invader detection chemistries for the field of colorectal cancer screening. Financial terms of the license agreement were not disclosed.
The Invader chemistry, which is being commercialized by Hologic’s subsidiary Third Wave Technologies, is a highly accurate, easy-to-use and rapid molecular detection platform that is easily combined with polymerase chain reaction, or PCR. Exact anticipates coupling the digital PCR technology it has exclusively licensed from Johns Hopkins University with the unique, quantitative detection capabilities of the Invader chemistry.
Exact’s Invader chemistry license becomes part of the broad intellectual property estate that positions the company as the sole player in the billion-dollar stool-based DNA, or sDNA, screening market. The company’s IP portfolio now includes exclusive licenses to key detection technologies, sDNA testing methods, and important biomarkers that will form the backbone of the company’s sDNA-based screening test.